— Exhibition Review —
The 3-day 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2024) came to a successful conclusion at the Shanghai New International Expo Center on June 21, 2024.
● Exhibition site
Jinran Bio once again made an appearance at this globally renowned industry event. At the exhibition site, Jinran Bio's booth was crowded with people, and domestic and foreign customers stopped to watch it, showing great interest and attention to the chiral compound synthesis technology displayed. Jinran Bio uses its leading and unique synthetic biology technology to not only improve the quality and purity of the product, but also greatly reduce production costs and environmental pollution, and contribute to the global green and sustainable development. In addition, Jinran Bio's strict control and complete quality system ensures the quality and safety of its products and has won the trust and praise of customers.
● Communication and negotiation
During the exhibition, Jinran Bio also had in-depth exchanges and discussions with many customers in the fields of medicine, health products, cosmetics, etc., and established extensive cooperative relationships. These customers highly praised Jinran Bio's technical strength and product quality, and expressed that they will further strengthen cooperation with Jinran Bio to jointly promote the development of related industries.
● Looking to the future
In short, Jinran Bio's wonderful appearance at the exhibition not only demonstrates its leading and unique technology, but also conveys its persistent pursuit of green, environmental protection and sustainable development. We have reason to believe that in the future development, Jinran Biotechnology will continue to make greater contributions to the innovation and development of the field of biological synthesis technology.
— Company Introduction—
Jinran Bio was established in June 2020. It is a high-quality chiral compounds and materials green intelligent manufacturing enterprise integrating R&D, production and sales. Relying on the founding team's more than ten years of experience in R&D and industrialization in synthetic biology, the company is committed to designing, developing, producing and selling new chiral molecules and materials.
Currently, the company has 4 major technology platforms and 7 product pipelines, and is committed to helping mankind realize his desire to create a better life through biosynthesis!
Post time: Jun-27-2024